One transdermal patch from a box of 7 used with the PassPort (TM) Applicator device for the delivery of basal insulin, made by Altea Therapeutics, US, c.2007. The insulin skin patch system is designed to improve and sustain levels of basal insulin to lower the risk of hypoglycemia, as well as ensure greater patient compliance than injecting insulin equivalents and also has the advantage of being stored at room temperature. The Applicator and transdermal patches are non-working models of the technology and do not contain insulin.

The insulin skin patch system is designed to maintain levels of basal insulin – background insulin – in the body. The device called the ‘Applicator’ is used to place a patch to the skin. Once applied, the patch is activated and starts delivering insulin. Applying insulin patches is believed to be more convenient than conventional injections, so it is hoped that people with diabetes will find it easier to maintain their insulin levels using this system.

The device lowers the risk of hypoglycaemia, which occurs when blood sugars are low due to an overdose of insulin, as the patch can be removed immediately. Insulin has to be stored in a refrigerator but the patches can be stored at room temperature. The product was developed by Altea Therapeutics.